TY - JOUR
T1 - Statins and the risks of stroke recurrence and death after ischemic stroke
T2 - The Fukuoka Stroke Registry
AU - Makihara, Noriko
AU - Kamouchi, Masahiro
AU - Hata, Jun
AU - Matsuo, Ryu
AU - Ago, Tetsuro
AU - Kuroda, Junya
AU - Kuwashiro, Takahiro
AU - Sugimori, Hiroshi
AU - Kitazono, Takanari
AU - Ishitsuka, Takao
AU - Fujimoto, Shigeru
AU - Ibayashi, Setsuro
AU - Kusuda, Kenji
AU - Arakawa, Shuji
AU - Irie, Katsumi
AU - Fujii, Kenichiro
AU - Wakugawa, Yoshiyuki
AU - Okada, Yasushi
AU - Yasaka, Masahiro
AU - Nagao, Tetsuhiko
AU - Ooboshi, Hiroaki
AU - Omae, Tsuyoshi
AU - Toyoda, Kazunori
AU - Nakane, Hiroshi
AU - Fukuda, Kenji
AU - Fukushima, Yoshihisa
AU - Tamaki, Kinya
AU - Sadoshima, Seizo
N1 - Funding Information:
Takanari Kitazono received honoraria from Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, and MSD K.K., and research support from Shionogi & Co., Ltd., AstraZeneca K.K., Kowa Pharmaceutical Ltd., Pfizer Inc., Astellas Pharma Inc., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Coompany, and MSD K.K.
Funding Information:
This study was funded in part by a Grant-in-Aid for Scientific Research (A 22249069) and the Coordination, Support and Training Program for Translational Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology.
PY - 2013/12
Y1 - 2013/12
N2 - Background and purpose: The findings of recent clinical trials suggest that treatment with high-dose statins reduces the risk of stroke recurrence. However, the doses approved in Japan are much lower than those in the previous studies. This study aimed to elucidate whether prescribed doses of statins reduce the risks of cerebrovascular events (CVEs: stroke recurrence or transient ischemic attack) and all-cause mortality in a cohort of Japanese patients with first-ever ischemic stroke. Methods: The 2822 eligible patients registered in the Fukuoka Stroke Registry with first-ever acute ischemic stroke from June 2007 to February 2011 were classified into statin users (n=993) and non-users (n=1829) at discharge, and followed up until March 2012. We assessed the cumulative risks of CVE and all-cause mortality by the Kaplan-Meier method, and calculated hazard ratios (HRs) and 95% confidential intervals (CIs) using the Cox proportional hazards model. Results: During the follow-up time (median, 2.0 years), 305 patients had CVEs and 345 died. The cumulative risks of CVE and death after 4 years were significantly lower in statin users than in non-users (13.8% versus 19.5%, P=0.005 for CVE; 11.8% versus 21.7%, P<0.001 for death). After adjusting for multiple confounding factors, statin treatment significantly reduced the risks of CVE (HR, 0.70; 95% CI, 0.53 to 0.92; P=0.011) and all-cause mortality (HR, 0.67; 95% CI, 0.50 to 0.89; P=0.006). Conclusions: Our findings suggest that low-dose statin may reduce the risks of CVE and death in Japanese patients with acute ischemic stroke.
AB - Background and purpose: The findings of recent clinical trials suggest that treatment with high-dose statins reduces the risk of stroke recurrence. However, the doses approved in Japan are much lower than those in the previous studies. This study aimed to elucidate whether prescribed doses of statins reduce the risks of cerebrovascular events (CVEs: stroke recurrence or transient ischemic attack) and all-cause mortality in a cohort of Japanese patients with first-ever ischemic stroke. Methods: The 2822 eligible patients registered in the Fukuoka Stroke Registry with first-ever acute ischemic stroke from June 2007 to February 2011 were classified into statin users (n=993) and non-users (n=1829) at discharge, and followed up until March 2012. We assessed the cumulative risks of CVE and all-cause mortality by the Kaplan-Meier method, and calculated hazard ratios (HRs) and 95% confidential intervals (CIs) using the Cox proportional hazards model. Results: During the follow-up time (median, 2.0 years), 305 patients had CVEs and 345 died. The cumulative risks of CVE and death after 4 years were significantly lower in statin users than in non-users (13.8% versus 19.5%, P=0.005 for CVE; 11.8% versus 21.7%, P<0.001 for death). After adjusting for multiple confounding factors, statin treatment significantly reduced the risks of CVE (HR, 0.70; 95% CI, 0.53 to 0.92; P=0.011) and all-cause mortality (HR, 0.67; 95% CI, 0.50 to 0.89; P=0.006). Conclusions: Our findings suggest that low-dose statin may reduce the risks of CVE and death in Japanese patients with acute ischemic stroke.
UR - http://www.scopus.com/inward/record.url?scp=84888112150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888112150&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2013.09.017
DO - 10.1016/j.atherosclerosis.2013.09.017
M3 - Article
C2 - 24267228
AN - SCOPUS:84888112150
VL - 231
SP - 211
EP - 215
JO - Atherosclerosis
JF - Atherosclerosis
SN - 0021-9150
IS - 2
ER -